JPMorgan Chase & Co. Sells 39,130 Shares of Inhibrx, Inc. (NASDAQ:INBX)

JPMorgan Chase & Co. trimmed its position in Inhibrx, Inc. (NASDAQ:INBX) by 88.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,135 shares of the company’s stock after selling 39,130 shares during the period. JPMorgan Chase & Co.’s holdings in Inhibrx were worth $80,000 at the end of the most recent quarter.

Inhibrx Stock Performance

NASDAQ INBX opened at $12.72 on Tuesday. Inhibrx, Inc. has a twelve month low of $10.80 and a twelve month high of $18.95. The stock’s 50 day moving average is $14.49 and its 200 day moving average is $14.64.

Insider Buying and Selling at Inhibrx

In other Inhibrx news, Director Jon Faiz Kayyem bought 69,686 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average cost of $14.23 per share, for a total transaction of $991,631.78. Following the completion of the transaction, the director now owns 51,093 shares of the company’s stock, valued at $727,053.39. This represents a -374.80 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 22.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Separately, JMP Securities reissued a “market perform” rating on shares of Inhibrx in a report on Wednesday, January 22nd.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.